Politecnico di Torino - Corso Duca degli Abruzzi, 24 - 10129 Torino, ITALY

+39 011 090 6100 info@tech-share.it

Intranasal NGF for the treatment of pediatric traumatic brain lesions

Intranasal administrationIschemic brain lesionsMucosal Atomizer DeviceNerve Growth FactorTraumatic brain lesions


The present invention concerns the modalities of intranasal administration of Nerve Growth Factor (NGF) through a MAD (Mucosal Atomizer Device) for the treatment of hypoxic-ischemic and traumatic brain lesions of neonatal and pediatric age. This method allows delivery of NGF to cerebral parenchyma in a non-invasive way and without any side effects.

Technical features

The Nerve Growth Factor (NGF) is a neurotrophin which encourages neurogenesis, neuronal growth, and differentiation and survival of neurons. NGF can be useful in counteracting damages caused by traumatic and/or hypoxic-ischemic brain lesions by promoting the growth of new nerve cells in brain tissue and the revascularization of ischemic areas.

The MAD is applicable as a syringe: the drug in the liquid state, while passing through its nozzle, is atomized into particles of 30 μm in diameter, which allows absorption in the nasal cavity.Therefore, MAD represents a simple and non-invasive device, capable of conveying drugs to the level of the Central Nervous System (CNS) through the nose-to-brain pathway in a very short time and without any side effects.

Possible Applications

  • Treatment of neurobehavioural and neurosensory deficits in subjects with hypoxic-ischemic and traumatic brain lesions;
  • Possible use in the treatment of other CNS neurodegenerative disorders such as Parkinson’s Disease and Alzheimer‘s Disease.


  • First pharmacological therapy for the treatment of neurological outcomes secondary to hypoxic-ischemic and traumatic brain lesions (see PET images enclosed herewith);
  • Excellent bioavailability of the drug;
  • Fast and safe route of administration;
  • Minimal invasiveness;
  • Excellent security profile.